Tumors with EML4-ALK and other ALK fusions had a significantly lower median TMB (3.1 mut/Mb; 3.9 mut/Mb) compared to those with non-fusion ALK alterations (11.7 mut/Mb) and driver gene negative tumors (10.2 mut/Mb) yet had a significantly higher frequency of high PD-L1 TPS scores (scores ≥50%) than the other tumor groups (36% vs ≤23%) (Figure 2A). The gene discussed is CD274; the disease is neoplasm.